IL261536B - Treatment and prevention of infectious diseases caused by the Zika virus - Google Patents
Treatment and prevention of infectious diseases caused by the Zika virusInfo
- Publication number
- IL261536B IL261536B IL261536A IL26153618A IL261536B IL 261536 B IL261536 B IL 261536B IL 261536 A IL261536 A IL 261536A IL 26153618 A IL26153618 A IL 26153618A IL 261536 B IL261536 B IL 261536B
- Authority
- IL
- Israel
- Prior art keywords
- virus
- composition
- antibody
- antibodies
- fetus
- Prior art date
Links
- 241000907316 Zika virus Species 0.000 title claims description 73
- 208000015181 infectious disease Diseases 0.000 title claims description 31
- 238000011321 prophylaxis Methods 0.000 title claims description 12
- 208000035473 Communicable disease Diseases 0.000 title description 5
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 210000003754 fetus Anatomy 0.000 claims description 107
- 239000012634 fragment Substances 0.000 claims description 62
- 241000700605 Viruses Species 0.000 claims description 61
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 23
- 230000003053 immunization Effects 0.000 claims description 21
- 238000002649 immunization Methods 0.000 claims description 21
- 238000006386 neutralization reaction Methods 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 15
- 208000001455 Zika Virus Infection Diseases 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 11
- 241000710781 Flaviviridae Species 0.000 claims description 10
- 208000001490 Dengue Diseases 0.000 claims description 9
- 206010012310 Dengue fever Diseases 0.000 claims description 9
- 208000035332 Zika virus disease Diseases 0.000 claims description 9
- 208000025729 dengue disease Diseases 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 9
- 208000004141 microcephaly Diseases 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000003152 Yellow Fever Diseases 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000003070 absorption delaying agent Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000007951 isotonicity adjuster Substances 0.000 claims description 3
- 230000000670 limiting effect Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 238000002523 gelfiltration Methods 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 238000001728 nano-filtration Methods 0.000 claims description 2
- 230000032696 parturition Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000011519 second-line treatment Methods 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 description 20
- 241000710831 Flavivirus Species 0.000 description 17
- 230000009385 viral infection Effects 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
- 230000008774 maternal effect Effects 0.000 description 13
- 208000036142 Viral infection Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 206010014599 encephalitis Diseases 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 241000710842 Japanese encephalitis virus Species 0.000 description 7
- 201000006449 West Nile encephalitis Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000725619 Dengue virus Species 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 5
- 241000710772 Yellow fever virus Species 0.000 description 5
- 210000004381 amniotic fluid Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229940051021 yellow-fever virus Drugs 0.000 description 5
- 241000256111 Aedes <genus> Species 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000002669 amniocentesis Methods 0.000 description 4
- 230000004641 brain development Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 208000034423 Delivery Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 201000004296 Zika fever Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000009237 prenatal development Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000009677 vaginal delivery Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241000907333 Spondweni virus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000618849 Aedes africanus Species 0.000 description 1
- 241001221830 Aedes furcifer Species 0.000 description 1
- 241001221827 Aedes luteocephalus Species 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 1
- 241000369374 Hypocrella raciborskii Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 208000003140 Kyasanur forest disease Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302842P | 2016-03-03 | 2016-03-03 | |
| PCT/IL2017/050243 WO2017149528A1 (en) | 2016-03-03 | 2017-02-27 | Intrauterine therapy and prophylaxis of infectious diseases in a mammal fetus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL261536A IL261536A (en) | 2018-10-31 |
| IL261536B true IL261536B (en) | 2022-07-01 |
Family
ID=59743561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261536A IL261536B (en) | 2016-03-03 | 2017-02-27 | Treatment and prevention of infectious diseases caused by the Zika virus |
Country Status (3)
| Country | Link |
|---|---|
| BR (2) | BR112018067353A2 (pt) |
| IL (1) | IL261536B (pt) |
| WO (1) | WO2017149528A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110343172B (zh) * | 2018-04-04 | 2021-09-03 | 中国科学院微生物研究所 | 一种高灵敏度的黄热病毒人源单克隆抗体及其应用 |
| MX2020014154A (es) * | 2018-06-21 | 2021-05-12 | Emergent Biosolutions Canada Inc | Anticuerpo neutralizante zika y composiciones y metodos para usarlo. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110150904A1 (en) * | 2005-07-25 | 2011-06-23 | Avianax, Llc | Therapeutic Antibodies for Treatment and Prophylaxis of Transmittable Viral Diseases |
-
2017
- 2017-02-27 BR BR112018067353A patent/BR112018067353A2/pt unknown
- 2017-02-27 IL IL261536A patent/IL261536B/en unknown
- 2017-02-27 WO PCT/IL2017/050243 patent/WO2017149528A1/en active Application Filing
-
2018
- 2018-09-19 BR BR132018069012A patent/BR132018069012E2/pt unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110150904A1 (en) * | 2005-07-25 | 2011-06-23 | Avianax, Llc | Therapeutic Antibodies for Treatment and Prophylaxis of Transmittable Viral Diseases |
Non-Patent Citations (1)
| Title |
|---|
| NIGRO, GIOVANNI, ET AL., PASSIVE IMMUNIZATION DURING PREGNANCY FOR CONGENITAL CYTOMEGALOVIRUS INFECTION, 29 September 2005 (2005-09-29) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL261536A (en) | 2018-10-31 |
| WO2017149528A1 (en) | 2017-09-08 |
| BR112018067353A2 (pt) | 2019-01-15 |
| BR132018069012E2 (pt) | 2020-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pierson et al. | The emergence of Zika virus and its new clinical syndromes | |
| Wang et al. | MERS-CoV spike protein: targets for vaccines and therapeutics | |
| Fowler et al. | Maternally acquired Zika antibodies enhance dengue disease severity in mice | |
| JP6993401B2 (ja) | 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法 | |
| Zellweger et al. | Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease | |
| US10294293B2 (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof | |
| CN111344302B (zh) | 特异性结合至寨卡病毒表位的多特异性抗体及其用途 | |
| JP6957355B2 (ja) | 血清型交差反応性デング熱中和抗体及びその使用 | |
| US11834494B2 (en) | Antibodies to zika virus and methods of use thereof | |
| Zhao et al. | Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model | |
| CA2569142A1 (en) | Sars vaccines and methods to produce highly potent antibodies | |
| Kurup et al. | Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract | |
| IL261536B (en) | Treatment and prevention of infectious diseases caused by the Zika virus | |
| JP2021520854A (ja) | 黄熱を処置するための方法および組成物 | |
| US20230065377A1 (en) | Human antibodies to alphaviruses | |
| US10689435B2 (en) | Therapy and prophylaxis of infectious disease caused by zika virus | |
| TWI511977B (zh) | 抗登革熱病毒非結構性蛋白１之單株抗體及其用途 | |
| AU2016217679A1 (en) | Filovirus therapy | |
| Gupta et al. | Equine immunoglobulin fragment F (ab’) 2 displays high neutralizing capability against multiple SARS-CoV-2 variants | |
| WO2022241760A1 (en) | Safer vaccines | |
| RU2816182C2 (ru) | Усовершенствованная коронавирусная вакцина | |
| US20230072640A1 (en) | Human monoclonal antibodies against yellow fever virus and uses therefor | |
| WO2023131262A1 (zh) | 特异性结合SARS-CoV-2的抗原结合蛋白 | |
| US20210147514A1 (en) | Zika neutralizing antibody compositions and methods of using the same | |
| Newbery | Chikungunya virus infection: A review |